A “gold standard” trial found that semaglutide helped reduce drinking in people with obesity who sought out treatment for ...
Semaglutide cut heavy drinking days by about 41%, the study found.
The FBI director has until April 28 to answer 10 questions about his relationship with alcohol.
Novo Nordisk (NYSE:NVO) is exploring semaglutide as a potential treatment for alcohol use disorder, expanding beyond its current uses in diabetes and obesity. The company has also begun Phase 1 trials ...
Once-weekly semaglutide was tied to a reduction in heavy drinking days among adults with obesity and alcohol use disorder, ...
Heart surgeon Dr Jeremy shares insights after 1,500 days alcohol-free, emphasising improved mental clarity, emotional ...